Overnight	O
switching	B:C2936279
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
:	O
an	O
observational	O
study	I:C1518527
.	O

Overnight	O
switching	O
from	O
oxcarbazepine	B:C0069751
to	O
eslicarbazepine	O
acetate	I:C2725262
:	O
an	O
observational	O
study	I:C1518527
.	O

Overnight	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
:	O
an	O
observational	O
study	I:C1518527
.	O

Overnight	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
:	O
an	O
observational	B:C1518527
study	I:C1518527
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	B:C2936279
patients	O
from	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
(	O
oxcarbazepine	O
)	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
eslicarbazepine	O
acetate	I:C2725262
)	O
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	O
patients	O
from	O
immediate	B:C1708470
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
(	O
oxcarbazepine	O
)	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
eslicarbazepine	O
acetate	I:C2725262
)	O
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	O
patients	O
from	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	B:C0069751
(	O
oxcarbazepine	O
)	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
eslicarbazepine	O
acetate	I:C2725262
)	O
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	O
patients	O
from	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
(	O
oxcarbazepine	B:C0069751
)	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
eslicarbazepine	O
acetate	I:C2725262
)	O
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	O
patients	O
from	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
(	O
oxcarbazepine	O
)	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
(	O
eslicarbazepine	O
acetate	I:C2725262
)	O
.	O

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	O
patients	O
from	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
(	O
oxcarbazepine	O
)	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
transitioning	O
patients	O
overnight	O
from	O
oxcarbazepine	B:C0069751
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

We	O
investigated	O
the	O
effects	O
of	O
transitioning	O
patients	O
overnight	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
.	O

A	O
retrospective	B:C0035363
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	B:C2603343
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	B:C0014547
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	B:C1708470
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	B:C0069751
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	B:C2936279
overnight	O
to	O
eslicarbazepine	O
acetate	I:C2725262
.	O

A	O
retrospective	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsy	I:C0014547
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	I:C1708470
release	I:C1708470
oxcarbazepine	O
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	O
overnight	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
.	O

Patients	O
were	O
switched	B:C2936279
because	O
they	O
experienced	O
persistent	O
seizures	O
with	O
oxcarbazepine	O
but	O
were	O
unable	O
to	O
tolerate	O
increased	O
oxcarbazepine	O
dosing	O
due	O
to	O
adverse	O
events	I:C0041755
.	O

Patients	O
were	O
switched	O
because	O
they	O
experienced	O
persistent	O
seizures	B:C0036572
with	O
oxcarbazepine	O
but	O
were	O
unable	O
to	O
tolerate	O
increased	O
oxcarbazepine	O
dosing	O
due	O
to	O
adverse	O
events	I:C0041755
.	O

Patients	O
were	O
switched	O
because	O
they	O
experienced	O
persistent	O
seizures	O
with	O
oxcarbazepine	B:C0069751
but	O
were	O
unable	O
to	O
tolerate	O
increased	O
oxcarbazepine	O
dosing	O
due	O
to	O
adverse	O
events	I:C0041755
.	O

Patients	O
were	O
switched	O
because	O
they	O
experienced	O
persistent	O
seizures	O
with	O
oxcarbazepine	O
but	O
were	O
unable	B:C1299582
to	O
tolerate	O
increased	O
oxcarbazepine	O
dosing	O
due	O
to	O
adverse	O
events	I:C0041755
.	O

Patients	O
were	O
switched	O
because	O
they	O
experienced	O
persistent	O
seizures	O
with	O
oxcarbazepine	O
but	O
were	O
unable	O
to	O
tolerate	O
increased	O
oxcarbazepine	B:C0069751
dosing	O
due	O
to	O
adverse	O
events	I:C0041755
.	O

Patients	O
were	O
switched	O
because	O
they	O
experienced	O
persistent	O
seizures	O
with	O
oxcarbazepine	O
but	O
were	O
unable	O
to	O
tolerate	O
increased	O
oxcarbazepine	O
dosing	O
due	O
to	O
adverse	B:C0041755
events	I:C0041755
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	B:C0282574
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	B:C0282574
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	B:C0282574
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	B:C0282574
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	B:C1443086
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	B:C0037585
Battery	I:C0037585
for	I:C0037585
Attention	I:C0037585
Performance	I:C0037585
version	I:C0037585
2.3	I:C0037585
.	O

Assessments	B:C1261322
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

Assessments	O
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	B:C2936279
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

Assessments	O
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	O
from	O
oxcarbazepine	B:C0069751
to	O
eslicarbazepine	O
acetate	I:C2725262
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

Assessments	O
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

The	O
analysis	B:C0936012
included	O
21	O
patients	O
(	O
12	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	I:C0243095
36	I:C0243095
years	I:C0243095
)	O
.	O

The	O
analysis	O
included	O
21	O
patients	O
(	O
12	O
women	B:C0043210
,	O
9	O
men	O
;	O
mean	O
age	I:C0243095
36	I:C0243095
years	I:C0243095
)	O
.	O

The	O
analysis	O
included	O
21	O
patients	O
(	O
12	O
women	O
,	O
9	O
men	B:C0025266
;	O
mean	O
age	I:C0243095
36	I:C0243095
years	I:C0243095
)	O
.	O

The	O
analysis	O
included	O
21	O
patients	O
(	O
12	O
women	O
,	O
9	O
men	O
;	O
mean	B:C0243095
age	I:C0243095
36	I:C0243095
years	I:C0243095
)	O
.	O

After	O
switching	B:C2936279
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O

After	O
switching	O
from	O
oxcarbazepine	B:C0069751
to	O
eslicarbazepine	O
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O

After	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O

After	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	B:C0282574
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O

After	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	B:C0282574
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O

After	O
switching	O
from	O
oxcarbazepine	O
to	O
eslicarbazepine	O
acetate	I:C2725262
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
Adverse	O
Events	I:C0282574
Profile	I:C0282574
(	O
P<.001	O
)	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
(	O
P=.001	O
)	O
,	O
and	O
alertness	B:C1443086
(	O
P<.05	O
)	O
.	O

Adverse	B:C0282574
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	O
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	O
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	O
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

Adverse	O
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	B:C0184511
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	O
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	O
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

Adverse	O
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	O
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	B:C0282574
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	O
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	O
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

Adverse	O
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	O
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	B:C0184511
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	O
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

Adverse	O
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	O
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	O
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	B:C1443086
scores	O
improved	O
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

Adverse	O
Events	I:C0282574
Profile	I:C0282574
total	O
scores	O
improved	O
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
Quality	O
of	I:C0282574
Life	I:C0282574
in	I:C0282574
Epilepsy	I:C0282574
Inventory	I:C0282574
10	I:C0282574
total	O
scores	O
improved	O
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	B:C0184511
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	B:C2603343
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	B:C2936279
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	B:C0069751
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	B:C2725262
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	B:C0014547
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	B:C2825142
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	B:C0041755
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	I:C2603343
center	I:C2603343
study	I:C2603343
,	O
an	O
overnight	O
switch	O
from	O
twice	O
-	O
daily	O
oxcarbazepine	O
to	O
once	O
-	O
daily	O
eslicarbazepine	O
acetate	I:C2725262
in	O
patients	O
with	O
drug	O
-	I:C0013203
resistant	I:C0013203
focal	O
epilepsies	I:C0014547
resulted	O
in	O
improvements	O
in	O
side	O
effects	I:C0041755
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	B:C1443086
.	O

